33620 Results

People

  1. Ladanyi
    Ladanyi
  2. Giralt
    Giralt
  3. Motzer
    Motzer
  4. Reuter
    Reuter
  5. Perales
    Perales
  6. Scher
    Scher
  7. Zelenetz
    Zelenetz
  8. Berger
    Berger
  9. Al-Ahmadie
    Al-Ahmadie
  10. O'Reilly
    O'Reilly

Groups

  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)
  7. Department of Pathology and Laboratory Medicine (5172)
  8. Surgery (4871)
  9. Sloan Kettering Institute Faculty (3826)
  10. Sloan Kettering Institute Postdocs (3612)
  1. "Meeting abstract"
Formats
  1. Meeting Abstract (33620)
Groups
  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)

More Groups

People
  1. Marc Ladanyi (641)
  2. Sergio Giralt (632)
  3. Robert Motzer (574)
  4. Victor Reuter (568)
  5. Miguel-Angel Perales (482)
  6. Howard Scher (463)

More People

Years
  1. 2025 (295)
  2. 2024 (1694)
  3. 2023 (1954)
  4. 2022 (2196)
  5. 2021 (1731)
  6. 2020 (1901)

More Years

Publications
  1. Journal of Clinical Oncology (6252)
  2. Blood (3939)
  3. Laboratory Investigation (1846)
  4. Cancer Research (1822)
  5. International Journal of Radiation Oncology, Biology, Physics (1643)
  6. Modern Pathology (1494)

More Publications

Publishers
  1. American Society of Clinical Oncology (6251)
  2. Elsevier Inc. (4694)
  3. American Society of Hematology (3939)
  4. American Association for Cancer Research (3045)
  5. Nature Publishing Group (2151)
  6. Oxford University Press (2096)

More Publishers

Results (33620)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Results from the first phase 1 clinical study of the B-cell maturation antigen (BCMA) NEX T chimeric antigen receptor (CAR) T cell therapy CC-98633/BMS-986354 in patients (pts) with relapsed/refractory multiple myeloma (RRMM)
    Meeting Abstract

    Costa, L. J.; Kumar, S. K.; Atrash, S.; Liedtke, M.; Kaur, G.; Derman, B. A.; Bergsagel, P. L.; Mailankody, S.; McCarthy, P. L.; Limones, J.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Initial treatment response is prognostic and predictive of relapse patterns: Outcomes of >500 patients treated for primary CNS lymphoma
    Meeting Abstract

    Tringale, K. R.; Yahalom, J.; Scordo, M.; Cederquist, G. Y.; Vachha, B.; Schaff, L.; Hajj, C.; Hubbeling, H.; Zhang, Z.; White, C.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • A phase 2 study of pembrolizumab (MK-3475) after autologous stem cell transplantation in patients with T-cell non-Hodgkin lymphoma
    Meeting Abstract

    Merrill, M. H.; Dahi, P. B.; Redd, R. A.; McDonough, M. M.; Chen, Y. B.; LaCasce, A. S.; Fisher, D. C.; Herrera, A. F.; Jacobson, C. A.; Kim, A. I.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Risk profiling of patients with previously untreated diffuse large B-cell lymphoma (DLBCL) by measuring circulating tumor DNA (ctDNA): Results from the POLARIX study
    Meeting Abstract

    Herrera, A. F.; McCord, R.; Kimes, P.; Jardin, F.; Lenz, G.; Trneny, M.; Flowers, C. R.; Sehn, L. H.; Salles, G.; Sharman, J. P.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Liquid biopsy-based next-generation sequencing is an alternative to tissue molecular profiling of lymphoid, plasma-cell, and myeloid neoplasms
    Meeting Abstract

    Mata, D. A.; Lee, J. K.; Decker, B.; Shanmugam, V.; Marcus, C. B.; Tukachinsky, H.; Schrock, A. B.; Patel, N. R.; Ross, J. S.; Oxnard, G. R.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Unmatched whole-genome sequencing as a clinical tool for hematological neoplasms with significant utility in cases with tumor-in-normal contamination
    Meeting Abstract

    GutieĢrrez-Abril, J.; Leongamornlert, D.; Shukla, N. N.; Sulis, M. L.; Zhou, Y.; Levine, M. F.; Barretta, E.; Lee, S.; Arango-Ossa, J. E.; Gundem, G.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Impact of epichaperome inhibitor PU-H71 on anti-tumor T cell responses and its implications for immune and cellular therapy
    Meeting Abstract

    Martinet, J.; Sugita, M.; Alhomoud, M.; Abad, C.; Chiosis, G.; Roboz, G. J.; Boyer, O.; Guzman, M. L.
    Blood (2022)

    Fulltext@MSK | Save
  • Combined genetic ablation of CD54 and CD58 in car engineered cytotoxic lymphocytes effectively averts allogeneic immune cell rejection
    Meeting Abstract

    Hammer, Q.; Perica, K.; Mbofung, R. M.; van Ooijen, H.; Varady, E.; Jelcic, M.; Pan, Y.; Momayyezi, P.; Groff, B.; Abujarour, R.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Attenuation of graft-versus-host-disease via genetic or pharmacologic inhibition of the RNA splicing factor RBM39
    Meeting Abstract

    Bourcier, J.; Hogg, S. J.; Erickson, C.; Singer, M. E.; Tittley, S.; Ito, T.; Egorova, A.; Kuttiyara, J.; Hanash, A. M.; Abdel-Wahab, O.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Microbial bile acid metabolism shapes effector T cell responses during inflammation in mouse and human
    Meeting Abstract

    Lindner, S.; Miltiadous, O.; Ramos, R. J.; Dai, A.; Kousa, A.; Armijo, G. K.; Ghale, R.; Nguyen, C. L.; Paredes Sanchez, J.; Fei, T.; more...
    Blood (2022)

    Fulltext@MSK | Save